Galapagos doses first patient with novel CF corrector GLPG2222
Feb 01, 2017 21:02 pm UTC| Business
IND opening triggers $10 million milestone payment from AbbVie Mechelen, Belgium; 1 February 2017 - Galapagos NV (Euronext NASDAQ: GLPG) announces dosing of the first patient with cystic fibrosis (CF) Class III...
Qorvo® Reports Fiscal 2017 Third Quarter Results
Feb 01, 2017 21:01 pm UTC| Business
GREENSBORO, N.C., Feb. 01, 2017 -- Highlights On a GAAP basis, fiscal 2017 third quarter revenue was $826.3 million, gross margin was 37.6%, operating income was $61.4 million, and loss per share was $0.62On a...
CymaBay Announces Proposed Public Offering of Common Stock
Feb 01, 2017 21:01 pm UTC| Business
NEWARK, Calif., Feb. 01, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet need, today...
Brooks Automation Reports Results for the Fiscal First Quarter of 2017 Ended December 31, 2016
Feb 01, 2017 21:01 pm UTC| Business
CHELMSFORD, Mass., Feb. 01, 2017 -- Brooks Automation, Inc. (Nasdaq:BRKS), a leading worldwide provider of automation and cryogenic solutions for multiple markets, including semiconductor manufacturing and life...
Amdocs Limited Reports Record Quarterly Revenue of $955M
Feb 01, 2017 21:01 pm UTC| Business
Raises Fiscal 2017 Revenue Growth Outlook to 2.5-6.5% YoY in Constant Currency Reiterates Fiscal 2017 Non-GAAP Diluted EPS Growth Outlook of 4.5%-8.5% YoY Key highlights: First fiscal quarter revenue of $955 million,...
Kamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6
Feb 01, 2017 21:01 pm UTC| Business
NESS ZIONA, Israel, Feb. 01, 2017 -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the...
Feb 01, 2017 21:01 pm UTC| Business
TEL AVIV, Israel, Feb. 01, 2017 -- Bioblast Pharma Ltd. (NasdaqGM:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced new clinical and development updates related to its proprietary...